Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination
Publication year
2011Source
Clinical Cancer Research, 17, 13, (2011), pp. 4541-9ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Oncology
Anesthesiology
Laboratory of Medical Immunology
Tumorimmunology
Medical Microbiology
IQ Healthcare
Pathology
Health Evidence
Urology
Paediatrics - OUD tm 2017
Former Organization
Epidemiology, Biostatistics & HTA
Journal title
Clinical Cancer Research
Volume
vol. 17
Issue
iss. 13
Page start
p. 4541
Page end
p. 9
Subject
N4i 1: Pathogenesis and modulation of inflammation NCMLS 1: Infection and autoimmunity; N4i 4: Auto-immunity, transplantation and immunotherapy NCMLS 2: Immune Regulation; NCEBP 2: Evaluation of complex medical interventions; NCEBP 6: Quality of nursing and allied health care; NCEBP 7: Effective primary care and public health; NCMLS 2: Immune Regulation; ONCOL 2: Age-related aspects of cancer; ONCOL 3: Translational research; ONCOL 3: Translational research NCMLS 2: Immune RegulationAbstract
PURPOSE: The tyrosine kinase inhibitors sorafenib and sunitinib have efficacy in several types of cancer. Recent studies indicate that these agents affect the immune system. The way it affects the immune response to influenza vaccination is unknown. The aim of this study was to elucidate the specific immune response to seasonal flu vaccination in cancer patients treated with sunitinib or sorafenib. Patients and Methods: Sunitinib- or sorafenib-treated cancer patients were vaccinated against seasonal influenza with an inactivated vaccine. Healthy controls and patients with metastatic renal cell cancer (mRCC) without systemic treatment (nontreated mRCC controls) were included for comparison. Antibody responses were measured at baseline, day 8, and day 22 by a standard hemagglutination inhibition assay and cellular T-cell responses at baseline and day 8 by proliferation assay and secretion of cytokines. RESULTS: Forty subjects were enrolled: 16 patients treated with sunitinib, 6 patients with sorafenib, 7 nontreated mRCC controls, and 11 healthy controls. All patients treated with sunitinib and sorafenib developed seroprotection rates comparable with controls. Functional T-cell reactivity was observed in all groups, except for patients treated with sorafenib who showed a decreased proliferation rate and IFN-gamma/IL-2 production and increased IL-10 compared with healthy controls. CONCLUSION: We conclude that influenza vaccination should be recommended to cancer patients treated with sunitinib or sorafenib.
This item appears in the following Collection(s)
- Academic publications [238441]
- Electronic publications [122508]
- Faculty of Medical Sciences [90373]
- Open Access publications [97504]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.